Charles Schwab
FENC icon

Charles Schwab’s Fennec Pharmaceuticals FENC Stock Holding History

Charles Schwab’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Buy
70,504
+6,967
+11% +$56.9K ﹤0.01% 3099
2026
Q1 		$391K Buy
63,537
+6,288
+11% +$48.5K ﹤0.01% 3181
2025
Q4 		$441K Hold
57,249
– – ﹤0.01% 3194
2025
Q3 		$536K Sell
57,249
-4,038
-7% -$35K ﹤0.01% 3155
2025
Q2 		$509K Buy
61,287
+141
+0.2% +$965 ﹤0.01% 3134
2025
Q1 		$372K Hold
61,146
– – ﹤0.01% 3155
2024
Q4 		$386K Buy
61,146
+5,694
+10% +$29.2K ﹤0.01% 3212
2024
Q3 		$277K Hold
55,452
– – ﹤0.01% 3300
2024
Q2 		$339K Buy
55,452
+13,955
+34% +$116K ﹤0.01% 3334
2024
Q1 		$461K Hold
41,497
– – ﹤0.01% 3059
2023
Q4 		$466K Hold
41,497
– – ﹤0.01% 3094
2023
Q3 		$312K Hold
41,497
– – ﹤0.01% 3205
2023
Q2 		$366K Buy
+41,497
New +$345K ﹤0.01% 3178
2021
Q2 		– Sell
-45,870
Closed -$285K – 3459
2021
Q1 		$285K Hold
45,870
– – ﹤0.01% 3258
2020
Q4 		$342K Buy
45,870
+2,880
+7% +$21.9K ﹤0.01% 3110
2020
Q3 		$261K Sell
42,990
-3,594
-8% -$25.3K ﹤0.01% 3086
2020
Q2 		$389K Buy
+46,584
New +$346K ﹤0.01% 2931
2019
Q2 		– Sell
-27,211
Closed -$132K – 3234
2019
Q1 		$132K Buy
27,211
+6,111
+29% +$40.2K ﹤0.01% 3075
2018
Q4 		$135K Hold
21,100
– – ﹤0.01% 3067
2018
Q3 		$174K Hold
21,100
– – ﹤0.01% 3089
2018
Q2 		$221K Buy
+21,100
New +$250K ﹤0.01% 3051

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Charles Schwab's FENC Position: Q2 2026 in Review

Charles Schwab increased its Fennec Pharmaceuticals (FENC) stake by 11% in Q2 2026, buying an estimated $56.9K and bringing the position to 70,504 shares worth $758K. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

Charles Schwab first reported a position in FENC in Q2 2018 and has held it in 21 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Charles Schwab held 70,504 shares of Fennec Pharmaceuticals worth $758K as of Q2 2026.
  • Charles Schwab bought 6,967 Fennec Pharmaceuticals shares in Q2 2026, an estimated $56.9K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3099 holding.
  • Charles Schwab first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 21 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.